Last reviewed · How we verify
Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients). Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months
Details
| Lead sponsor | University Hospital, Limoges |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 420 |
| Start date | 1999-08 |
| Completion | 2010-12 |
Conditions
- Cancer
Interventions
- warfarine - low molecular heparin
Primary outcomes
- Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis : — Day90
- Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy — Day90
Countries
France